A Randomized, Multicenter, Double-Blind Study to Compare the Efficacy of Single-Day Treatment (1000 mg b.i.d.) With Famciclovir Compared to That of Placebo in Patient-Initiated Episodic Treatment of Recurrent Genital Herpes in Immunocompetent Black Patients.

Trial Profile

A Randomized, Multicenter, Double-Blind Study to Compare the Efficacy of Single-Day Treatment (1000 mg b.i.d.) With Famciclovir Compared to That of Placebo in Patient-Initiated Episodic Treatment of Recurrent Genital Herpes in Immunocompetent Black Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Mar 2011

At a glance

  • Drugs Famciclovir (Primary)
  • Indications Herpes genitalis; Herpes simplex virus type 2 infections
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 02 Feb 2010 Status changed from active, no longer recruiting to completed.
    • 13 Jan 2010 Primary endpoint 'Time to clinical response' has not been met.
    • 13 Jan 2010 Results published in Current Medical Research and Opinion.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top